The National COVID-19 Clinical Evidence Taskforce (NCCET) provides clinical COVID-19 guidelines which are updated on a regular basis with the latest research. Where evidence is available recommendations are evidence based; consensus is also used. Clinicians should refer to NCCET Living Guidelines for the latest recommendations surrounding drug treatments for COVID-19.

Clinicians should also refer to the following NSW resources which have been produced to assist with the safe and appropriate use of COVID-19 therapeutics:

As of 22 August 2022, the following medicines are provisionally approved by the TGA (see COVID-19 treatments: Provisional registrations for up to date information) and available in NSW for use in the management of COVID-19. The provisional approval pathway allows sponsors to apply for time-limited provisional registration on the Australian Register of Therapeutic Goods (ARTG). It provides access to certain promising new medicines where we assess that the benefit of early availability of the medicine outweighs the risk inherent in the fact that additional data are still required (see Provisional approval pathway: prescription medicines for further information).

Refer to the relevant Product Information for the approved indication(s) and dosing regimens.

  • Casirivimab and imdevimab (Ronapreve)
  • Molnupiravir (Lagevrio)
  • Nirmatrelvir plus ritonavir (Paxlovid)
  • Remdesivir (Veklury)
  • Sotrovimab (Xevudy)
  • Tixagevimab and cilgavimab (Evusheld)
  • Tocilizumab (Actemra).

Where the proposed use of a medicine for COVID-19 is off-label or contrary to the approved indication or dosing regimens, standard procedures must be followed as per PD2016_033 Approval Process of Medicines for Use in NSW Public Hospitals. Examples include:

Document information

Developed by

Drug and therapeutics Advisory Community of Practice.

Consultation

Endorsed by

Dr Nigel Lyons, Deputy Secretary, Health System Strategy and Planning, NSW Ministry of Health.

Reviewed date

24 August 2022.

For use by

All communities of practice.


​​
Current as at: Monday 29 August 2022
Contact page owner: Health Protection NSW